當(dāng)前位置：首頁 > 產(chǎn)品中心 > 細(xì)胞培養(yǎng)產(chǎn)品 > 類器官/干細(xì)胞培養(yǎng)/細(xì)胞培養(yǎng) > 類器官Hydrocortisone
簡要描述：類器官Hydrocortisone類器官（Organoids）是指將成體干細(xì)胞或多能干細(xì)胞在體外三維培養(yǎng)形成的具有一定空間結(jié)構(gòu)的組織類似物。類器官在組織結(jié)構(gòu)、細(xì)胞類型、自我更新能力和功能等方面與來源組織高度一致，從而在發(fā)育生物學(xué)、疾病造模、精準(zhǔn)醫(yī)學(xué)、藥物研發(fā)、基因和細(xì)胞療法、感染和免疫以及再生醫(yī)學(xué)等生物醫(yī)學(xué)的多個領(lǐng)域展現(xiàn)出*的優(yōu)勢。
產(chǎn)品型號：廠商性質(zhì)：代理商更新時間：2025-04-09訪 問 量：638產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | 其他品牌 | 供貨周期 | 現(xiàn)貨 |
|---|
類器官Hydrocortisone類器官（Organoids）是指將成體干細(xì)胞或多能干細(xì)胞在體外三維培養(yǎng)形成的具有一定空間結(jié)構(gòu)的組織類似物。類器官在組織結(jié)構(gòu)、細(xì)胞類型、自我更新能力和功能等方面與來源組織高度一致，從而在發(fā)育生物學(xué)、疾病造模、精準(zhǔn)醫(yī)學(xué)、藥物研發(fā)、基因和細(xì)胞療法、感染和免疫以及再生醫(yī)學(xué)等生物醫(yī)學(xué)的多個領(lǐng)域展現(xiàn)出*的優(yōu)勢。
產(chǎn)品介紹
DESCRIPTION
| Background | Hydrocortisone is a steroid hormone or glucocorticoid secreted by the adrenal cortex[1]. | ||
| Alias | Cortisol；氫化可的松；17-羥基皮質(zhì) (甾) 酮；皮質(zhì)甾醇；氫化皮質(zhì)素 | ||
| M. W t | 362.46 | ||
| Formula | C21H30O5 | ||
| CAS No | 50-23-7 | ||
| Storage | Powder | -20 °C | 3 years |
| In solvent | -80 °C | 6 months | |
| -20 °C | 1 month | ||
| Solubility | DMSO H2O : < 0.1 mg/mL | ≥ 31 mg/mL(85.53 mM) | |
| Ethanol | 23 mg/mL(63.46 mM) | ||
| H2O | < 0.1 mg/mL(insoluble) | ||
BIOLOGICAL ALTIVITY
In Vitro
Hydrocortisone (50 nM) shows a dose-dependent down-regulation of GR transcript in hCMEC/D3 cells. Hydrocortisone supplementation of the serum-reduced cell differentiation medium leads to a significant increase in TER across the hCMEC/D3 monolayer[1]. Hydrocortisone-treated Dendritic cells (DCs) show a decreased expression of MHC II molecules, the costimulatory molecule CD86, and the DC-specific marker CD83, as well as a strongly reduced IL-12 secretion. Hydrocortisone-treated DCs inhibit production of IFN-γ but induce an increased release of IL-4 and no change in IL-5[2]. Hydrocortisone reduces postischemic oxidative stress, perfusion pressure, and transudate formation. Hydrocortisone inhibits postischemic shedding of syndecan-1, heparan sulfate, and hyaluronan as is release of histamine from resident mast cells[3].
In Vivo
| NCT00621985 | Boston Children′s Hospital | Adrenal Hyperplasia, Congenital | Phase 2 |
| NCT03910088 | Cairo University | Post-Dural Puncture Headache | Phase 4 |
| NCT00657306 | University of Turin, Italy | Cirrhosis With Ascites | Phase 2 |
類器官Hydrocortisone
產(chǎn)品咨詢
掃一掃，關(guān)注微信
電話
微信掃一掃